GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » ROC (Joel Greenblatt) %

REVB (Revelation Biosciences) ROC (Joel Greenblatt) % : -10,242.34% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Revelation Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -10,242.34%.

The historical rank and industry rank for Revelation Biosciences's ROC (Joel Greenblatt) % or its related term are showing as below:

REVB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13181.82   Med: -10523.8   Max: -9192.31
Current: -11360.4

During the past 5 years, Revelation Biosciences's highest ROC (Joel Greenblatt) % was -9192.31%. The lowest was -13181.82%. And the median was -10523.80%.

REVB's ROC (Joel Greenblatt) % is ranked worse than
92.73% of 1403 companies
in the Biotechnology industry
Industry Median: -300.47 vs REVB: -11360.40

Revelation Biosciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Revelation Biosciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Revelation Biosciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences ROC (Joel Greenblatt) % Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
- -9,192.31 -9,877.27 -11,170.32 -13,181.82

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,682.35 -10,640.56 -13,540.94 -9,457.89 -10,242.34

Competitive Comparison of Revelation Biosciences's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Revelation Biosciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's ROC (Joel Greenblatt) % falls into.



Revelation Biosciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.118) - (4.062 + 0 + 0.0049999999999999)
=-3.949

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.067) - (1.911 + 0 + 0.0029999999999999)
=-1.847

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Revelation Biosciences for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.016/( ( (0.081 + max(-3.949, 0)) + (0.056 + max(-1.847, 0)) )/ 2 )
=-7.016/( ( 0.081 + 0.056 )/ 2 )
=-7.016/0.0685
=-10,242.34 %

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (NAS:REVB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Revelation Biosciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Executives
George F Tidmarsh director, 10 percent owner
Lakhmir S Chawla director 1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l other: Former 10% owner 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif other: Former 10% Owner 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a. other: Former 10% owner 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris other: Former 10% owner 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd other: Former 10% owner 22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa other: Former 10% owner 25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke director, officer: Chief Executive Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver director 725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii officer: Chief Financial Officer 3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis 10 percent owner 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc 10 percent owner 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606